Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Diabetes Therapy to Improve BMI and Lung Function in CF
This study is currently recruiting patients.
Sponsored by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Cystic Fibrosis Foundation
Novo Nordisk Pharmaceuticals
|
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Purpose
To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF).
Condition | Treatment or Intervention | Phase |
---|---|---|
Cystic Fibrosis Diabetes Mellitus |
Drug: Insulin Aspart Drug: Rapaglinide |
Phase III |
MedlinePlus related topics: Cystic Fibrosis; Diabetes
Genetics Home Reference related topics: cystic fibrosis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Expected Total Enrollment: 150
Study start: June 2001
The primary objective of this research is to determine whether treatment with either insulin or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and pulmonary function in cystic fibrosis patients who have diabetes without fasting hyperglycemia.
Eligibility
Ages Eligible for Study: 16 Years and above, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |